Lixudebart is CSL and Alentis USD 1.6 billion bet on claudin-1, spanning rare kidney diseases and the unmet treatment need in PSC.
Cancer care is entering a new phase as blood-based detection and drug combinations create new paths for earlier diagnosis and stronger treatment.
India dengue vaccine efforts gain relevance as Bangladesh sees its deadliest dengue month of 2026 and Indian cities report rising post-monsoon cases. Qdenga adds a new preventive tool as transmission patterns become less predictable.
The government extends import price curbs on two pharma raw materials, offering domestic producers temporary relief from low-priced Chinese supplies.
Engineered LC3 could make autophagy more programmable, giving researchers greater control over the cell-cleansing pathway. The CSIR-IGIB-led study explores its potential as a therapeutic platform for cancer and neurodegenerative diseases.
India powers primary care through 1.86 lakh Ayushman Arogya Mandirs, delivering 420 million screenings and expanding preventive healthcare nationwide.
Long-acting immunology antibodies are central to Sanofi and Regeneron's expanded alliance, with USD 1 billion upfront and up to USD 7 billion in milestones as they build beyond Dupixent.
The latest updates highlight three strong mid-stage results in the pharma pipeline, as Eli Lilly, Merck, and AbbVie advance promising therapies toward Phase 3 trials.
Pharma pricing faces tighter scrutiny this month as courts, state regulators and global agreements target drug, device and hospital supply-chain markups.
Wegovy pill users switching from injectable GLP-1 drugs lost 4.1 percent of their body weight in three months, highlighting a potential new pathway for treatment continuity.
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")